Safety evaluation of Sodium-glucose cotransporter 2 inhibitors for cancer risk in specific populations

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, have demonstrated benefits in reducing cardiovascular and renal events. However, heart failure (HF) and chronic kidney disease (CKD) are prevalent comorbidities in T2DM.

Educational Objectives

Educational Aim:

To assess the long-term safety of SGLT2 inhibitor, particularly concerning cancer risk in these populations.

Educational Outcomes:
Upon completion of this module practitioners should have a clear understanding of:

1. Sodium-glucose cotransporter 2 (SGLT2) inhibitors.
2. The use of SGLT2 inhibitors in different patient populations.

Instructions for this Module

• Read the supplied reading material and complete the quiz that follows;
• You have three attempts to pass the quiz;
• The pass grade is 70%;
• You need to pass the quiz to claim your CPD certificate;
• Please click on the CPD certificate link below to claim your CPD certificate and to update your CPD Manager.

If you need any assistance to complete this module, please Contact us